All In Biotech

Drug Trial Radar · NCT04739826

Flumatinib Versus Nilotinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia

Evaluating Efficacy and Safety of Flumatinib Versus Nilotinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia(CML-CP) : A Multicenter, Open-lable, Real World Study

Last checked: Nov 19, 2026Latest source record: Nov 3, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

491

Planned (sponsor's estimate)

Start

Sep 25, 2020

Primary completion

Jan 2025

Study completion Dec 2025

Sponsor

Lead sponsor
The First Affiliated Hospital of Soochow UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Feb 5, 2021

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The ultimate goal of CML treatment is to improve survival, including overall survival (OS), progression-free survival (PFS), event-free survival (EFS), and treatment-free remission (TFR). TFR is a new therapeutic goal for chronic myeloid leukemia in chronic phase (CML-CP). In ENESTnd and DASISION trials, both nilotinib and dasatinib achieved DMR more effectively than imatinib. In the guidelines for diagnosis and treatment of chronic myeloid leukemia in China (2020 edition), flumatinib has been recommended as an appropriate first-line treatment for newly diagnosed chronic phase chronic myeloid leukemia (CML-CP) patients. There is no doubt that the second-generation TKIs show great advantages in deep molecular response, which further increases the possibility of achieving treatment-free remission. However, there is no direct comparative study to determine which TKI is better for de novo CML-CP. Thus, we conducted a multi-center, open-lable and real world study to compare the efficacy and safety between flumatinib and nilotinib.

Conditions

  • CML, Chronic Phase; TKI

Interventions

  • Flumatinib MesylateDrug

    Flumatinib mesylate tablets 600mg qd

  • Nilotinib PillDrug

    Nilotinib Capsules 300mg bid

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Major molecular response rate at 12 monthsTime frame: 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology

    Suzhou, Jiangsu, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.